About: MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Sector: Healthcare
Industry: Biotechnology
Latest price: $55.87 (+2.44%)
MBX NASDAQ MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc. Common Stock share price
MBX price activity
Last Price
$55.870
Change (24hr)
1.33 USD (2.44%)
Volume
666.73K
Volume (4w avg)
-
Open
$53.72
Day Range
$52.29 - $56.52
Previous Close
$54.54
Last Trade
30 Oct, 8:17 pm GMT+0
Delayed
30 Oct, 8:17 pm GMT+0
MBX price performance
Delayed
30 Oct, 8:17 pm GMT+0
MBX Market Signals